China Resources Jiangzhong Pharmaceutical Co.,Ltd(600750.SS)
No price history available.
Key financial summary
Financials in CNY| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | 2026E | ||
|---|---|---|---|---|---|---|---|---|---|
| Total revenue | CNYm | 2,441 | 2,874 | 3,885 | 4,553 | 4,435 | 4,185 | N/A | N/A |
| Operating profit | CNYm | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Net profit | CNYm | 474 | 506 | 598 | 719 | 788 | 906 | N/A | N/A |
| EPS reported | CNY | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Operating cashflow per share | CNY | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Capex per share | CNY | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| FCF per share | CNY | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Free cash flow | CNYm | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Net debt | CNYm | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Book value equity | CNYm | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Book value per share | CNY | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Number of shares | m | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| DPS (TTM paid) | CNY | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
Financial summary
Financials in CNY| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | 2026E | ||
|---|---|---|---|---|---|---|---|---|---|
| Value | |||||||||
| P/E LTM | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| P/B LTM | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| P/S LTM | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| P/FCF LTM | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| EV/EBITDA LTM | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| EV/Sales LTM | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Earnings Yield LTM | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| FCF Yield | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Quality | |||||||||
| ROE | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| ROIC | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Operating margin | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Gross margin | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| FCF/Sales | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Growth and momentum | |||||||||
| EPS Growth YoY | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Sales Growth YoY | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Net Income Growth YoY | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| FCF Growth | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Operating Profit Growth | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Dividend and capital structure | |||||||||
| Dividend Yield | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Dividend Growth | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Payout Ratio | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| FCF/Debt | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Net Debt/EBITDA | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| EBIT/Net interest | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Net debt/market cap | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Net debt/Equity | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Gross debt/equity | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
Ratings
Based on consensus from external analysts. Not Kvantra's opinion.
Company overview
China Resources Jiangzhong Pharmaceutical Co.,Ltd functions as a prominent Chinese manufacturer of a wide array of pharmaceutical products for the domestic market. Its extensive product portfolio includes a variety of over-the-counter (OTC) medications, such as tablets designed for stomach-strengthening and digestion promotion, lactobacillus tablets, and triple live bifidobacterium enteric-coated capsules. Other significant OTC offerings feature compound fresh bamboo juice liquid, compound coral lozenges, multivitamin tablets, Fritillaria and loquat capsules, bezoar and snake gallbladder Fritillaria liquid, and compound gold melon seed. Beyond pharmaceutical drugs, the company also provides health consumer goods. These range from general nourishing products and rehabilitation nutrition items to specialized solutions for gastrointestinal and liver health. Furthermore, China Resources Jiangzhong Pharmaceutical manufactures prescription drugs. This segment encompasses a broad selection of Traditional Chinese Medicine (TCM) products, including Shenbao capsules, Paishi granules, Huangba Shengmai drink, Bazhen Yimu capsules, Zhenju Jiangya tablets, Shuangju granules, Zhikang tablets, and Shuxiong granules. It also produces chemical medications such as lumbrokinase enteric-coated capsules, Rabelagat sodium enteric-coated tablets, and chloroprocaine hydrochloride. Additionally, the company processes and supplies essential medicinal raw materials, including stir-fried Chinese jujube seeds, French pinellia, and vinegar-soaked northern bupleurum. The company, headquartered in Nanchang, China, was established in 1996. It was formerly identified as Jiang Zhong Pharmaceutical Co.,Ltd before officially adopting its current name, China Resources Jiangzhong Pharmaceutical Co.,Ltd, in January 2025.
Similar companies
For informational purposes only. Kvantra provides data and quantitative analysis, not investment advice. KvantraRank is a mechanical model output. Analyst price targets and ratings are sourced from third parties and are not Kvantra recommendations. Past performance does not guarantee future results; all investments carry risk.
China Resources Jiangzhong Pharmaceutical Co.,Ltd (600750.SS)
No price history available.
Based on consensus from external analysts. Not Kvantra's opinion.
China Resources Jiangzhong Pharmaceutical Co.,Ltd functions as a prominent Chinese manufacturer of a wide array of pharmaceutical products for the domestic market. Its extensive product portfolio includes a variety of over-the-counter (OTC) medications, such as tablets designed for stomach-strengthening and digestion promotion, lactobacillus tablets, and triple live bifidobacterium enteric-coated capsules. Other significant OTC offerings feature compound fresh bamboo juice liquid, compound coral lozenges, multivitamin tablets, Fritillaria and loquat capsules, bezoar and snake gallbladder Fritillaria liquid, and compound gold melon seed. Beyond pharmaceutical drugs, the company also provides health consumer goods. These range from general nourishing products and rehabilitation nutrition items to specialized solutions for gastrointestinal and liver health. Furthermore, China Resources Jiangzhong Pharmaceutical manufactures prescription drugs. This segment encompasses a broad selection of Traditional Chinese Medicine (TCM) products, including Shenbao capsules, Paishi granules, Huangba Shengmai drink, Bazhen Yimu capsules, Zhenju Jiangya tablets, Shuangju granules, Zhikang tablets, and Shuxiong granules. It also produces chemical medications such as lumbrokinase enteric-coated capsules, Rabelagat sodium enteric-coated tablets, and chloroprocaine hydrochloride. Additionally, the company processes and supplies essential medicinal raw materials, including stir-fried Chinese jujube seeds, French pinellia, and vinegar-soaked northern bupleurum. The company, headquartered in Nanchang, China, was established in 1996. It was formerly identified as Jiang Zhong Pharmaceutical Co.,Ltd before officially adopting its current name, China Resources Jiangzhong Pharmaceutical Co.,Ltd, in January 2025.